A Phase 3 interventional study of Minimally invasive surgery for esophageal cancer using near-infrared indocyanine green fluorescence to visualize the sentinel lymph node in Esophageal Cancer, Sentinel Lymph Node and Lymphadenectomy, sponsored by Fujian Medical University Union Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Fujian Medical University Union Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.
Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 139th largest by planned enrollment of the 394 interventional ones that give a count, is one of 31 that started in 2026, is one of 62 in phase 3, reaches primary completion later than 174 of the 237 other live ones, and was the 413th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Sanofi · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
502 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 189 · Phase 3 69 · Phase 4 8
First in 1995; this study’s year is marked. 31 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 80 across the 394 interventional studies, 300 across the 108 observational. Of the 120 that completed or were terminated, 7 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 502 have an industry lead sponsor. The 10 most frequent:
Fujian Medical University Union Hospital is the lead sponsor of 109 studies on the registry; 79 are open to participants now.
Fujian Medical University Union Hospital has 8 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
61 of the studies in Esophageal Neoplasms with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04513808Phase 3The Cleveland ClinicTotal Intravenous Anesthesia and Recurrence Free Survival | 2026-12 |
| NCT04415853Phase 3Sunshine Lake Pharma Co., Ltd.Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | 2027-08 |
| NCT07303231Phase 3Fujian Medical University Union HospitalThe Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy | 2027-08-01 |
| NCT05252078Jiangxi Provincial Cancer HospitalAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | 2026-11 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 61 to your calendar (.ics) → With an account.
Among the 502 studies in Esophageal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sentinel lymph nodes, as the primary site of tumor metastasis, play a pivotal role in assessing patient prognosis and planning subsequent treatment strategies. The investigators plan to conduct a multicenter, prospective cohort study to evaluate the effectiveness of indocyanine green (ICG)-guided near-infrared imaging in tracing sentinel lymph node during esophageal squamous cell carcinoma (ESCC) surgery, compared with the gold standard of complete lymph node dissection (CLND), in detecting metastatic disease. This study aims to address the following core questions:
Participants will:
This study will be accepted in esophageal cancer patients with Radical Esophag-ectomy as the research object. The investigators will divide participants into two groups: experimental group for injection of indocyanine green group and control group for injectable in-docyanine green group.The investigators will compare with the accuracy,false positive rate and false negative rate,sensitivity, specificity and related indicators of intraoperative lymph node cleaning,in order to explore the common position of esophageal cancer sentinel lymph node,guidance of esophageal cancer lymph node cleaning thoroughly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Minimally invasive surgery for esophageal cancer using near-infrared indocyanine green fluorescence to visualize the sentinel lymph node
A multicenter, prospective cohort study will be conducted. Enrolled patients with esophageal squamous cell carcinoma will undergo minimally invasive radical esophagectomy. During surgery, ICG will be injected around the tumor under gastroscopy guidance, and fluorescent lymph nodes will be tracked using a thoracoscopic near-infrared camera. These lymph nodes will be grouped and marked by professional thoracic surgeons, and intraoperative frozen pathology results will be recorded. Subsequent CLND will be performed. The study will collect and analyze patients' clinical information, ICG imaging results, and pathological examination results to explore the effectiveness of the ICG imaging system.
Accuracy rate of lymph node dissection
According to postoperative pathological results, investigate the detection rate of metastatic lymph nodes using the near-infrared indocyanine green fluorescence imaging system in lymph node dissection for esophageal squamous cell carcinoma
Time frame: 1 week after operation
Sensitivity and specificity of lymph node dissection
Sensitivity and specificity of lymph node dissection of each arm(according to postoperative pathology)
Time frame: 1 week after operation
The number of lymph nodes
The number of lymph nodes between the both groups
Time frame: 1 week after operation
False positive rate of lymph node dissection
False positive rate of lymph node dissectionof each arm(according to postoperative pathology)
Time frame: 1 week after operation
False negative rate of lymph node dissection
False negative rate of lymph node dissection of each arm(according to postoperative pathology)
Time frame: 1 week after operation
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Aug 2027, 19 months later.
Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fujian Medical University Union Hospital →